Every material Form 8-K RECURSION PHARMACEUTICALS, INC. has filed with the SEC since September 21, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Recursion reported third-quarter 2026 results, with total revenue of $18.6 million, up from $5.2 million a year earlier, and a net loss of $119.0 million, down from $162.3 million. The company said its cash runway now extends into 2029, including proceeds from an October 2026 offering, and that Fred Hassan was appointed Chair of the Board effective October 31, 2026.
Total revenue was $18.6 million for Q3 2026 versus $5.2 million for Q3 2025, driven mainly by a $10.0 million Sanofi milestone
Net loss was $119.0 million, or $0.22 per share, versus $162.3 million, or $0.36 per share, a year earlier
Cash, cash equivalents and restricted cash were $561.5 million at September 30, 2026; pro forma about $748.7 million including about $187.2 million in offering proceeds
Fred Hassan was appointed Chair of the Board effective October 31, 2026
Recursion agreed to sell 61,540,000 new Class A common shares at $3.25 each, for expected gross proceeds of about $200 million, with closing expected October 16, 2026. The company also reported preliminary cash of about $561 million as of September 30, 2026, which it says will fund operations into 2029, and released updated Phase 1b/2 data for REC-4881 and news of a Sanofi option on a development candidate.
Offering of 61,540,000 Class A shares at $3.25 per share, with expected gross proceeds of about $200 million before fees and expenses, closing expected October 16, 2026
Executive officers and directors agreed to a 45-day lock-up on sales of company securities, subject to exceptions
Preliminary cash, cash equivalents and restricted cash of about $561 million as of September 30, 2026; company expects funding into 2029
Sanofi optioned a development candidate, triggering a $10 million milestone payment and bringing total collaboration payments to $144 million
On September 15, 2026, Recursion amended its master agreement with Tempus AI, extending the term to six years, removing its right to terminate for convenience, and setting annual license fees at $14 million on each of the third, fourth and fifth anniversaries, with at least $4 million payable in cash. The same day, Recursion granted Tempus a non-exclusive oncology license to its TxFM Model for a $12 million fee, paid in two $6 million installments. The filing does not state the financial effect of either agreement on Recursion's results.
The Amendment, dated September 15, 2026, extends the Master Agreement term from five to six years and eliminates Recursion's right to terminate for convenience.
Annual license fees are revised to $14 million on each of the third, fourth and fifth anniversaries, replacing the prior schedule of $22 million, $32 million and $42 million.
The TxFM License Agreement, also dated September 15, 2026, grants Tempus a two-year, non-exclusive oncology license with a $12 million fee.
The Amendment reduces the aggregate number of unique de-identified data records Recursion may access.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every RECURSION PHARMACEUTICALS, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →